![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Tenaya Therapeutics Inc | NASDAQ:TNYA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.11 | -3.67% | 2.89 | 2.81 | 2.96 | 3.04 | 2.785 | 2.99 | 449,052 | 22:16:44 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading |
Name of exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 19, 2024, Leone Patterson, Chief Financial and Business Officer (“CFBO”) of Tenaya Therapeutics, Inc. (“Tenaya” or the “Company”), advised Tenaya that she was resigning from her role as CFBO, Principal Financial Officer and Principal Accounting Officer to pursue another opportunity. Ms. Patterson is expected to remain with Tenaya until August 14, 2024, to assist in the transition of her responsibilities. Ms. Patterson’s resignation is not the result of any disagreement with Tenaya on any matter relating to Tenaya’s financials, operations, policies or practices. Tenaya has initiated a search for a new Chief Financial Officer.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TENAYA THERAPEUTICS, INC. | ||||||
By: | /s/ Jennifer Drimmer Rokovich | |||||
Jennifer Drimmer Rokovich | ||||||
General Counsel and Secretary | ||||||
Date: July 25, 2024 |
Document and Entity Information |
Jul. 19, 2024 |
---|---|
Cover [Abstract] | |
Amendment Flag | false |
Entity Central Index Key | 0001858848 |
Document Type | 8-K |
Document Period End Date | Jul. 19, 2024 |
Entity Registrant Name | Tenaya Therapeutics, Inc. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-40656 |
Entity Tax Identification Number | 81-3789973 |
Entity Address, Address Line One | 171 Oyster Point Boulevard |
Entity Address, Address Line Two | Suite 500 |
Entity Address, City or Town | South San Francisco |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94080 |
City Area Code | (650) |
Local Phone Number | 825-6990 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, $0.0001 par value per share |
Trading Symbol | TNYA |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
1 Year Tenaya Therapeutics Chart |
1 Month Tenaya Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions